Intra-Cellular Therapies acquisition will expand J&J’s presence in neurology space, says…
GlobalData forecasts that, as a therapy for schizophrenia, Caplyta could drive sales of approximately $229 million by 2033 in the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Schizophrenia
Schizophrenia market to reach $17 billion in 7MM by 2031, forecasts GlobalData
Pipeline innovations set to drive schizophrenia market growth despite generic competition
Cobenfy could break dopamine dominance in schizophrenia treatment: GlobalData
Cobenfy is a twice-daily oral medication that combines xanomeline, a muscarinic receptor agonist, and trospium chloride, a…
Zydus gains final USFDA approval for Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and…
The tablets are indicated for the acute and maintenance treatment of schizophrenia
Neurocrine’s drug cuts schizophrenia symptoms in mid-stage study
The Neurocrine drug belongs to a new class of treatments that target proteins called muscarinic receptors in the central nervous…
FDA denial could delay launch of Minerva’s schizophrenia treatment roluperidone by at least two…
To address the clinical deficiencies stated in the CRL, Minerva must provide additional safety and efficacy data for roluperidone…
Karuna Therapeutics’ NDA for KarXT accepted by USFDA
If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades
Zydus gets USFDA nod for Prochlorperazine Maleate Tablets
Prochlorperazine tablets are used to treat nervous, emotional and mental conditions, and non-psychotic anxiety
Zydus Cadila gets USFDA approval for Fluphenazine Hydrochloride Tablets
This medication is used to treat symptoms of a certain type of mental/mood condition (schizophrenia)
Dr Reddy’s launch Fluphenazine Hydrochloride Tablets in US
Fluphenazine hydrochloride is a trifluoromethyl phenothiazine derivative intended for the management of schizophrenia